News

Catch up on coverage from the first day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Hawkes highlights groundbreaking therapies for psoriasis, including new oral medications and IL-23 inhibitors.

At Maui Derm NP+PA Fall 2024, Melodie Young, MSN, ANP-c, reviews new treatment options for pediatric patients with psoriasis and details the difference in disease manifestation between adults and children.

The IL-13 inhibitor, recently FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin of color.

George Martin, MD, and Ted Rosen, MD, reprise their popular session on new therapies and products with a fast and furious rundown of the current armamentarium across disease states.

At Maui Derm NP+PA Fall, Sheila Fallon Friedlander, MD, reviews key findings for the pediatric population from recent dermatology literature, covering topics like cutaneous Crohn’s disease, interrupting the atopic march, advancements in gene therapy, and more.

The conference aimed at providing dermatology NPs and PAs clinicians with the latest updates in the specialty begins today in Nashville, Tennessee.

Keep up with the latest headlines in dermatology from the past week, including the use of AI in a dermatology clinic to enhance gun safety, decreased rates of melanoma in Swedish adults under 50, and more.

Ebglyss is now approved for children and adults aged 12 years and older.

In case you missed it, this week we had news about adverse event profiles among pediatric patients treated with JAK inhibitors, positive results from a phase 3 trial of dupilumab for chronic spontaneous urticaria, and the impact of tropical weather on patients with atopic dermatitis.

Armstrong shared insights on the recently released NPF psoriasis health indicator report including pearls on national health data and unmet needs in public health campaigns.

Misleading marketing and incomplete scientific data have led to widespread misinformation about botulinum toxin products.

Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.

Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.

Researchers reported several factors and indicators that may predict early-stage systemic sclerosis among patients in Japan.

The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.

Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.

The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.

A recent reviewed showed that self-stigma in patients with skin disease is influenced by body image issues and social support.

Shanna Miranti, MMS, PA-C, reviews 2 patient cases of pseudo acne fulminans, offering perspectives on treatment and management strategies.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between October and December. Share your thoughts with us by September 25.

New study results show promise in dupilumab for bullous pemphigoid, with 59% of patients avoiding disease relapse.

These positive data will support US regulatory submission by end of 2024.

Swiss researchers found significant gender differences in melanoma care, including variations in information preferences and treatment decision-making.

The review assessed infections, gastrointestinal AEs, blood and lymphatic disorders, and nervous system and musculoskeletal/connective tissue disorders.

Researchers stated the lack of reported clinical validation data raises concerns about their effectiveness and safety.

A recent review found glycyrrhizin improves minoxidil's efficacy in treating AA, showing reduced severity and improved hair density.

Researchers reported that second-year students were more likely to identify dermatological conditions, particularly in White patients.

It is important that dermatology providers can easily recognize and treat communicable sports dermatoses, writes Shanna Miranti, MMS, PA-C.

The study reported that UST leads in dose escalation frequency, but also had lower discontinuation rates when compared to ADA and ETN.